{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Analytical+Treatment+Interruption",
    "query": {
      "intervention": "Analytical Treatment Interruption"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 36,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Analytical+Treatment+Interruption&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T17:04:16.701Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01787994",
      "title": "Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2012-12",
      "completion_date": "2017-07",
      "has_results": false,
      "last_update_posted_date": "2019-08-30",
      "last_synced_at": "2026-09-04T17:04:16.701Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01787994"
    },
    {
      "nct_id": "NCT06032546",
      "title": "A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Immuno-deficiency Virus (HIV) Disease"
      ],
      "interventions": [
        {
          "name": "Budigalimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Budigalimab",
          "type": "DRUG"
        },
        {
          "name": "ABBV-382",
          "type": "DRUG"
        },
        {
          "name": "Placebo for ABBV-382",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 163,
      "start_date": "2023-10-12",
      "completion_date": "2025-09-22",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-09-04T17:04:16.701Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06032546"
    },
    {
      "nct_id": "NCT06104280",
      "title": "Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Opioid Use Disorder",
        "Sleep Disturbance"
      ],
      "interventions": [
        {
          "name": "Post-Illumination Pupillary Response (PIPR)",
          "type": "OTHER"
        },
        {
          "name": "Polysomnography",
          "type": "OTHER"
        },
        {
          "name": "Multiple Sleep Latency Test",
          "type": "OTHER"
        },
        {
          "name": "Ecological Momentary Assessments",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Actigraphy",
          "type": "DEVICE"
        },
        {
          "name": "DLMO",
          "type": "OTHER"
        },
        {
          "name": "Melatonin Suppression Test",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL",
        "DEVICE"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 200,
      "start_date": "2025-01-06",
      "completion_date": "2029-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-04T17:04:16.701Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06104280"
    },
    {
      "nct_id": "NCT03524430",
      "title": "RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Neoplasm Female"
      ],
      "interventions": [
        {
          "name": "Core needle biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Rna Diagnostics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 801,
      "start_date": "2018-04-26",
      "completion_date": "2031-05-22",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-09-04T17:04:16.701Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03524430"
    },
    {
      "nct_id": "NCT03721510",
      "title": "A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV/AIDS"
      ],
      "interventions": [
        {
          "name": "PGT121 + VRC07-523LS",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGT121 + VRC07-523LS + PGDM1400",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2018-12-03",
      "completion_date": "2022-05-02",
      "has_results": false,
      "last_update_posted_date": "2022-05-10",
      "last_synced_at": "2026-09-04T17:04:16.701Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03721510"
    },
    {
      "nct_id": "NCT02825797",
      "title": "3BNC117 and 10-1074 in HIV-infected Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV)"
      ],
      "interventions": [
        {
          "name": "3BNC117",
          "type": "DRUG"
        },
        {
          "name": "10-1074",
          "type": "DRUG"
        },
        {
          "name": "Analytical treatment interruption",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "2016-06",
      "completion_date": "2018-08-15",
      "has_results": false,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-09-04T17:04:16.701Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02825797"
    },
    {
      "nct_id": "NCT04223804",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV)",
        "HIV Infection",
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "ABBV-181",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 41,
      "start_date": "2020-01-30",
      "completion_date": "2023-02-27",
      "has_results": false,
      "last_update_posted_date": "2023-03-09",
      "last_synced_at": "2026-09-04T17:04:16.701Z",
      "location_count": 15,
      "location_summary": "Bakersfield, California • Los Angeles, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04223804"
    },
    {
      "nct_id": "NCT03815331",
      "title": "Xiaflex® Plus Testosterone Treatment Pilot Study Protocol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Peyronie's Disease (PD)"
      ],
      "interventions": [
        {
          "name": "Xiaflex®",
          "type": "DRUG"
        },
        {
          "name": "Aveed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Men's Health Boston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "18 Years to 70 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2019-01-14",
      "completion_date": "2020-12-30",
      "has_results": false,
      "last_update_posted_date": "2020-12-31",
      "last_synced_at": "2026-09-04T17:04:16.701Z",
      "location_count": 1,
      "location_summary": "Chestnut Hill, Massachusetts",
      "locations": [
        {
          "city": "Chestnut Hill",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03815331"
    },
    {
      "nct_id": "NCT02471326",
      "title": "VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "VRC-HIVMAB060-00-AB (VRC01)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2015-07-13",
      "completion_date": "2017-04-07",
      "has_results": true,
      "last_update_posted_date": "2017-10-31",
      "last_synced_at": "2026-09-04T17:04:16.701Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02471326"
    },
    {
      "nct_id": "NCT04155632",
      "title": "Neurocircuit Strategy to Decrease Cocaine Cue Reactivity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cocaine-Related Disorders"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Theta-burst stimulation (TBS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2020-12-18",
      "completion_date": "2023-03-09",
      "has_results": true,
      "last_update_posted_date": "2025-09-24",
      "last_synced_at": "2026-09-04T17:04:16.701Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04155632"
    }
  ]
}